Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K33/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/236426STAIN HIDING FABRIC WITH METALLIC COATING
WO 26.11.2020
Int.Class D06M 10/02
DTEXTILES; PAPER
06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D0664
10Physical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents or magnetic fields; Physical treatment combined with treatment with chemical compounds or elements
02ultrasonic or sonic; Corona discharge
Appl.No PCT/US2020/031571 Applicant MILLIKEN & COMPANY Inventor MONDAL, Rajib
This invention relates to a method for hiding stains in medical dressings and other textile substrates. The method includes applying a metallic silver coating to a textile substrate via a plasma enhanced chemical vapor deposition (PECVP) process. The metallic silver coating effectively hides any stain that comes into direct contact with the treated substrate by transferring the liquid beneath the surface of the coating. The invention also relates to textile substrates containing metallic silver coatings.
2.WO/2020/234195HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE
WO 26.11.2020
Int.Class A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245Oxadiazoles
Appl.No PCT/EP2020/063732 Applicant UNIVERSITAET ZUERICH Inventor HUGELSHOFER, Michael
The present invention relates generally to methods for treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF) comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp, or the functional analogue thereof, to form a complex with, and thereby neutralise, the cell-free Hb. Aspects of the invention further relate to compositions and kits of an artificial CSF comprising Hp.
3.WO/2020/234414USE OF METAL IONS TO POTENTIATE THE THERAPEUTIC EFFECTS OF ARSENIC
WO 26.11.2020
Int.Class A61K 33/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
36Arsenic; Compounds thereof
Appl.No PCT/EP2020/064189 Applicant MEDSENIC Inventor RIEGER, François
The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.
4.WO/2020/233372COOLING AND ANTI-ITCH ANTISEPTIC CREAM, AND PREPARATION METHOD THEREFOR
WO 26.11.2020
Int.Class A61K 9/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
06Ointments; Bases therefor
Appl.No PCT/CN2020/087652 Applicant ZHEJIANG OUJIE SCIENCE & TECHNOLOGY CO., LTD. Inventor LAN, Wenhua
A cooling and anti-itch antiseptic cream, comprising the following components in parts by weight: 4-6 parts of povidone iodine, 4.5-6 parts of rosin, 3-5 parts of Pelargonium citrosum extract, 2-4 parts of xanthan Gum, 0.5-1 parts of L-menthol, and 4-6 parts of liquid paraffin. The antiseptic cream has anti-itch, antiseptic, mosquito repellent, wound protecting, and infection avoiding effects.
5.20200360427COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS
US 19.11.2020
Int.Class A61K 33/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
18Iodine; Compounds thereof
Appl.No 16983177 Applicant CXL OPHTHALMICS, LLC Inventor Roy S. RUBINFELD

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

6.20200360647Use Of Inhaled Nitric Oxide For The Improvement Of Right And/Or Left Ventricular Function
US 19.11.2020
Int.Class A61M 16/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
16Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
10Preparation of respiratory gases or vapours
12by mixing different gases
Appl.No 16643167 Applicant Bellerophon Pulse Technologies LLC Inventor Deborah Quinn

Described herein are methods of using inhaled nitric oxide for improving and/or maintaining right ventricular function and/or left ventricular function. Some methods relate to the long-term administration of inhaled nitric oxide to a patient with pulmonary hypertension.

7.WO/2020/231297METHOD OF SORBING AND REMOVING HEAVY METAL PARTICLES FROM THE HUMAN BODY
WO 19.11.2020
Int.Class A61H 39/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
39Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
08Devices for applying needles to such points, i.e. for acupuncture
Appl.No PCT/RU2020/050049 Applicant BAKHMET'EV, Artem Olegovich Inventor BAKHMET'EV, Artem Olegovich
The invention relates to medicine, and more particularly to the sorption and removal of heavy metal particles and toxins from the human body using acupuncture. Acupuncture points are determined. At least 15 acupuncture needles are inserted at general acupuncture points of the body, and at least 15 acupuncture needles are inserted for localized acupuncture. The acupuncture needles are removed after 30-90 minutes. Said acupuncture needles comprise a handle and a rod, which are made of a metallic material. At least the working portion of the rod is covered with a coating based on magnetic nanoparticles of magnetite (Fe3O4) and/or maghemite (γ-Fe2O3). In one embodiment, the nanoparticle coating is applied by flame spraying. In another embodiment, the nanoparticles additionally comprise up to 20% silver and/or gold nanoparticles. In another embodiment, the size of the Fe3O4 nanoparticles is from 10 to 100 nm ± 20%. In another embodiment, the size of the γ-Fe2O3 nanoparticles does not exceed 20 nm. In another embodiment, a layer of magnetic nanoparticles of magnetite Fe3O4 and/or γ-Fe2O3 is additionally applied to the handle. In another embodiment, during application of the nanoparticle coating to the handle, the nanoparticles are applied in at least a double layer. Using this method makes it possible, as a result of the needle structure containing a coating based on magnetic particles of magnetite and/or maghemite, to reduce the concentration of harmful elements in the body.
8.WO/2020/228206METHOD FOR PREPARING CISPLATIN NANO-DRUG FOR TREATMENT OF OVARIAN CANCER
WO 19.11.2020
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Appl.No PCT/CN2019/105921 Applicant SOUTHERN MEDICAL UNIVERSITY Inventor WANG, Ying
A method for preparing a cisplatin nano-drug for the treatment of ovarian cancer. The method comprises the steps of: first coupling carboxylated heparin with folic acid and a tumor-targeting cyclopeptide (cRGD) to prepare a carboxylated heparin-folic acid-cyclopeptide, then adding cisplatin and mixing for reaction so as to chelate the cisplatin with the carboxylated heparin-folic acid-cyclopeptide, adding protamine after 24 hours of dialysis so as to connect together, by electric charge attraction, the positively charged protamine to the negatively charged carboxylated heparin-folic acid-cyclopeptide-cisplatin, and compress the cisplatin inside a carrier, and finally preparing a cisplatin nano-drug. The cisplatin nano-drug prepared by the method has significant effects of inhibiting cancer proliferation and metastasis, and has low toxicity and side effects.
9.20200360426PROTOCOL AND COMPOSITION FOR SUPPRESSION OF ALLERGIC RESPONSES
US 19.11.2020
Int.Class A61K 33/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
06Aluminium, calcium or magnesium; Compounds thereof
Appl.No 16524123 Applicant ISAAC ELIAZ Inventor ISAAC ELIAZ

A protocol for limiting the severity of allergic reactions, or preventing them entirely, is provided. The central feature of the protocol is the delivery, over a period of no more than an ninety minutes, of an amount of magnesium ranging from 50-500 mg magnesium, measured as elemental magnesium. A wide variety of salts and chelates of magnesium may be used. The magnesium is deliver via IV, at a relatively high rate, of no more than ninety and preferably about thirty minutes. IV bags, prepared for use in this invention, reflecting the instructions for use set forth above, are claimed as well.

10.20200360516TRACE ELEMENTS
US 19.11.2020
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No 16983008 Applicant WARBURTON TECHNOLOGY LIMITED Inventor Robert Naylor LAURIE

A trace element solution comprises selenium, zinc, manganese and copper at a concentration of at least 60 mg/ml. The solution may further comprise at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide.